[Antithrombotic drugs in atrial fibrillation].
Françoise Hidden‐Lucet
Abstract
Françoise Hidden‐Lucet
Abstract
Stroke and peripheral thrombo-embolism are common in all forms of atrial fibrillation which is responsible for a hypercoagulable state. Clinical and echocardiographic risk stratification allow therapeutic recommendations among the different antithrombotic strategies used in randomized studies (adjusted-dose oral anticoagulant, aspirin or a combination of aspirin and low-dose oral anticoagulant) in agreement with recent guidelines from the European and American associations of cardiology for the managMent of patients with atrial fibrillation.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Stroke and peripheral thrombo-embolism are common in all forms of atrial fibrillation which is responsible for a hypercoagulable state. Clinical and echocardiographic risk stratification allow therapeutic recommendations among the different antithrombotic strategies used in randomized studies (adjusted-dose oral anticoagulant, aspirin or a combination of aspirin and low-dose oral anticoagulant) in agreement with recent guidelines from the European and American associations of cardiology for the managMent of patients with atrial fibrillation.
Key concepts: Medicine, Antithrombotic, Atrial fibrillation, Aspirin, Cardiology, Risk stratification, Anticoagulant, Internal medicine